Toronto, Ontario – March 13, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...
Toronto, Ontario – February 27, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of...
Company to pursue regulatory filing for Phase I/II clinical study Toronto, Ontario – February 14, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company...
TORONTO, Feb. 01, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...
TORONTO – Kontrol Technologies Corp. (Cboe CA:KNR) (OTCQB:KNRLF) (FSE:1K8) (“Kontrol” or the “Company”) provides a corporate update for January 2024. Completion of High-Temperature Dry Kiln Pilot and Initial Technology Sale Following the press release dated...
TORONTO, Jan. 24, 2024 – REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is arranging a private placement of a maximum of 85,714,285 units (each, a “Unit”), at a price of $0.035 per Unit, for gross proceeds of up to $3...